Literature DB >> 16351685

Idealhalers or realhalers? A comparison of Diskus and Turbuhaler.

L Borgström1, L Asking, L Thorsson.   

Abstract

Medication for the treatment of asthma and chronic obstructive pulmonary disease should be given locally by inhalation. There is, however, no such thing as an ideal inhaler, or 'Idealhaler', which has all desired properties with no drawbacks. In this short review, we have compared the relative merits of the two most commonly used dry powder inhalers -- Turbuhaler and Diskus. Clinical effect is related to the amount of inhaled drug that reaches the lungs, and this in turn depends on the amount of fine particles generated at inhalation. Turbuhaler is more than twice as effective as Diskus at generating fine particles, and the higher lung deposition with Turbuhaler is accompanied by a lower variability in lung deposition. Compared with Diskus, the lung deposition with Turbuhaler is affected less by factors such as humidity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16351685     DOI: 10.1111/j.1368-5031.2005.00747.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  12 in total

1.  Fixed or adjustable maintenance-dose budesonide/formoterol compared with fixed maintenance-dose salmeterol/fluticasone propionate in asthma patients aged >or=16 years: post hoc analysis of a randomized, double-blind/open-label extension, parallel-group study.

Authors:  René Aalbers
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged > or =16 years with asthma: post hoc analysis of a randomized, double-blind study.

Authors:  Piotr Kuna
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

3.  Corticosteroid-induced gene expression in allergen-challenged asthmatic subjects taking inhaled budesonide.

Authors:  M M Kelly; E M King; C F Rider; C Gwozd; N S Holden; J Eddleston; B Zuraw; R Leigh; P M O'Byrne; R Newton
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

4.  Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections.

Authors:  Diana D Semler; Amanda D Goudie; Warren H Finlay; Jonathan J Dennis
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

5.  Effect of relative humidity on the electrostatic charge properties of dry powder inhaler aerosols.

Authors:  Philip Chi Lip Kwok; Hak-Kim Chan
Journal:  Pharm Res       Date:  2007-07-10       Impact factor: 4.200

6.  Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®).

Authors:  L Pekka Malmberg; Mark L Everard; Jussi Haikarainen; Satu Lähelmä
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-06-30       Impact factor: 2.849

7.  In Vitro Flow Rate Dependency of Delivered Dose and Fine Particle Dose of Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus with Patient Flow Rates Collected in a Randomized Controlled Trial.

Authors:  Rain Jõgi; Satu Lähelmä; Mikko Vahteristo; Anita Happonen; Jussi Haikarainen
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2018-10-09       Impact factor: 2.849

Review 8.  Recent advances in capsule-based dry powder inhaler technology.

Authors:  Federico Lavorini; Massimo Pistolesi; Omar S Usmani
Journal:  Multidiscip Respir Med       Date:  2017-05-22

9.  Inhaler competence and patient satisfaction with Easyhaler®: results of two real-life multicentre studies in asthma and COPD.

Authors:  Gabriella Gálffy; Györgyi Mezei; Gyula Németh; Lilla Tamási; Veronika Müller; Olof Selroos; Marta Orosz
Journal:  Drugs R D       Date:  2013-09

Review 10.  COPD: adherence to therapy.

Authors:  Alessandro Sanduzzi; Piero Balbo; Piero Candoli; Giousuè A Catapano; Paola Contini; Alessio Mattei; Giovanni Puglisi; Luigi Santoiemma; Anna A Stanziola
Journal:  Multidiscip Respir Med       Date:  2014-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.